Verstockt, BramAbreu, NéliaTorres, Joana2022-06-062022-06-062021Gastroenterology. 2021 Jul;161(1):353-3550016-5085http://hdl.handle.net/10451/53276© 2021 by the AGA InstituteThe topic of anti-TNF therapy discontinuation for patients with inflammatory bowel disease in long-term remission is of significance for both clinicians and patients, due to safety concerns, adverse effects, and cost. In the current pandemic era, it has regained renewed attention. However, disease relapse has been reported to occur in roughly 50% of patients, highlighting the need for the development of biomarkers that could help in selecting the best candidates for successful stopping.engjournal article10.1053/j.gastro.2021.05.0051528-0012